Crossmark

Second generation direct-acting antiviral (DAAs) Treatment on HCV+ patients: Patient reported outcomes (PROs) and psychiatric symptoms in a real world setting sample

Crossref DOI link: https://doi.org/10.1016/j.eurpsy.2017.02.230

Published Online: 2020-03-23

Published Print: 2017-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Moneglia, M.

Santangelo, A.

Burian, I.

Gragnani, L.

Elisa, F.

Quargnolo, M.

Pallanti, S.

Zignego, A.L.
License Information

License valid from 2020-03-23

Text and Data Mining valid from 2017-04-01
More Information

This article is maintained by: Elsevier

Article Title: Second generation direct-acting antiviral (DAAs) Treatment on HCV+ patients: Patient reported outcomes (PROs) and psychiatric symptoms in a real world setting sample

Journal Title: European Psychiatry

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eurpsy.2017.02.230

Content Type: simple-article

Copyright: Copyright © 2017 Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below